[{"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "phone": "44 203 9206789", "website": "https://www.centessa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Dr. Saurabh  Saha M.D., Ph.D.", "age": 45, "title": "CEO & Director", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": 957672, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gregory M. Weinhoff M.B.A., M.D.", "age": 51, "title": "Principal Accounting Officer & CFO", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 655004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David M. Chao Ph.D.", "age": 54, "title": "Chief Administrative Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 655004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tia L. Bush", "age": 51, "title": "Chief Technology & Quality Officer", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen K. Sheppard Esq., J.D.", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iqbal J. Hussain L.L.B.", "age": 41, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen M. Anderson", "age": 54, "title": "Chief People Officer", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Antoine  Yver M.D., M.Sc.", "age": 64, "title": "Executive VP & Chairman of Development", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 449579, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David John Grainger Ph.D.", "age": 53, "title": "Chief Innovation Officer", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harris L. Rotman Ph.D.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 8.0, "open": 8.05, "dayLow": 7.88, "dayHigh": 8.05, "regularMarketPreviousClose": 8.0, "regularMarketOpen": 8.05, "regularMarketDayLow": 7.88, "regularMarketDayHigh": 8.05, "payoutRatio": 0.0, "beta": 1.108, "forwardPE": -4.447222, "volume": 31239, "regularMarketVolume": 31239, "averageVolume": 148461, "averageVolume10days": 117180, "averageDailyVolume10Day": 117180, "bid": 7.92, "ask": 8.09, "bidSize": 2200, "askSize": 1400, "marketCap": 781522496, "fiftyTwoWeekLow": 3.0, "fiftyTwoWeekHigh": 8.65, "fiftyDayAverage": 6.7368, "twoHundredDayAverage": 5.8848, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 583195776, "profitMargins": 0.0, "floatShares": 40271129, "sharesOutstanding": 97629296, "sharesShort": 1699910, "sharesShortPriorMonth": 1325531, "sharesShortPreviousMonthDate": 1698710400, "dateShortInterest": 1701302400, "sharesPercentSharesOut": 0.0174, "heldPercentInsiders": 0.01784, "heldPercentInstitutions": 0.84626997, "shortRatio": 10.72, "shortPercentOfFloat": 0.0332, "impliedSharesOutstanding": 97629296, "bookValue": 2.659, "priceToBook": 3.0105305, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -157420992, "trailingEps": -1.65, "forwardEps": -1.8, "enterpriseToEbitda": -3.343, "52WeekChange": 1.4390244, "SandP52WeekChange": 0.24166095, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CNTA", "underlyingSymbol": "CNTA", "shortName": "Centessa Pharmaceuticals plc", "longName": "Centessa Pharmaceuticals plc", "firstTradeDateEpochUtc": 1622208600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "9f3bdf1d-ddc8-3bbd-88f7-8fed1cc82ba8", "messageBoardId": "finmb_704505677", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.005, "targetHighPrice": 15.0, "targetLowPrice": 8.0, "targetMeanPrice": 11.0, "targetMedianPrice": 11.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 281340992, "totalCashPerShare": 2.882, "ebitda": -174464000, "totalDebt": 83502000, "quickRatio": 8.918, "currentRatio": 9.511, "debtToEquity": 32.192, "returnOnAssets": -0.25491, "returnOnEquity": -0.49792, "freeCashflow": -109299872, "operatingCashflow": -180856000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "trailingPegRatio": null}]